Alexander D. Verin

Alexander D. Verin

Auto-generated profile, based on publicly available information

Alexander D. Verin

Vascular Biology Center, Medical College of Georgia, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2008 in Microvascular Research
Verified
Journal Article
Closed access
NBNatalia Bogatcheva
Natalia Bogatcheva
AVAlexander D. Verin
Alexander D. Verin

26 November 2010 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
AAAlexander S. Antonov
Alexander S. Antonov
GAGalina N. Antonova
Galina N. Antonova
DMDavid H. Munn
David H. Munn
NMNahid Mivechi
Nahid Mivechi
RLRudolf Lucas
Rudolf Lucas
AVAlexander D. Verin
Alexander D. Verin

1 May 2010 in Vascular Pharmacology
Verified
Journal Article
Closed access
NUNagavedi S. Umapathy
Nagavedi S. Umapathy
ZFZhengHong Fan
ZhengHong Fan
EZEvgeny A. Zemskov
Evgeny A. Zemskov
IAIrina B. Alieva
Irina B. Alieva
SBStephen M. Black
Stephen M. Black
AVAlexander D. Verin
Alexander D. Verin

1 September 2008 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
PDF file
CCCsilla Csortos
Csilla Csortos
ICIstvan Czikora
Istvan Czikora
NBNatalia Bogatcheva
Natalia Bogatcheva
DADjanybek M. Adyshev
Djanybek M. Adyshev
CPChristophe Poirier
Christophe Poirier
AVAlexander D. Verin
Alexander D. Verin
TGF-β-inhibited membrane-associated protein, TIMAP, is expressed at high levels in endothelial cells (EC). It is regarded as a member of the MYPT (myosin phosphatase target subunit) family of protein phosphatase 1 (PP1) regulatory subunits; however, its function in EC is not clear. In our pull-down experiments, recombinant TIMAP binds preferentially the β-isoform of the catalytic subunit of PP1 (PP1cβ) from pulmonary artery EC. As PP1cβ, but not PP1cα, binds with MYPT1 into functional complex, these results suggest that TIMAP is a novel regulatory subunit of myosin phosphatase in EC. TIMAP depletion by small interfering RNA (siRNA) technique attenuates increases in transendothelial electrical resistance induced by EC barrier-protective agents (sphingosine-1-phosphate, ATP) and enhances the effect of barrier-compromising agents (thrombin, nocodazole) demonstrating a barrier-protective role of TIMAP in EC. Immunofluorescent staining revealed colocalization of TIMAP with membrane/cytoskeletal protein, moesin. Moreover, TIMAP coimmunoprecipitates with moesin suggesting the involvement of TIMAP/moesin interaction in TIMAP-mediated EC barrier enhancement. Activation of cAMP/PKA cascade by forskolin, which has a barrier-protective effect against thrombin-induced EC permeability, attenuates thrombin-induced phosphorylation of moesin at the cell periphery of control siRNA-treated EC. On the contrary, in TIMAP-depleted EC, forskolin failed to affect the level of moesin phosphorylation at the cell edges. These results suggest the involvement of TIMAP in PKA-mediated moesin dephosphorylation and the importance of this dephosphorylation in TIMAP-mediated EC barrier protection.

1 September 2011 in Current Signal Transduction Therapy
Verified
Journal Article
Closed access
PDF file
AJAgnieszka Jezierska
Agnieszka Jezierska
IKIrina A. Kolosova
Irina A. Kolosova
AVAlexander D. Verin
Alexander D. Verin
This review summarizes the key role of Toll-Like Receptor (TLRs) molecules for igniting the immune system. Activated by a broad spectrum of pathogens, cytokines or other specific molecules, TLRs trigger innate immune responses. Published data demonstrate that the targeting and suppression of TLRs and TLR-related proteins with particular inhibitors may provide pivotal treatments for patients with cancer, asthma, sepsis, Crohns disease and thrombosis. Many drugs that target cytokines act in the late phases of the activated pathways, after the final peptides, proteins or glycoproteins are formed in the cell environment. TLR activity occurs in the early activation of cellular pathways; consequently inhibiting them might be most beneficial in the treatment of human diseases.

4 April 2011 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
AAAlexander S. Antonov
Alexander S. Antonov
GAGalina N. Antonova
Galina N. Antonova
MFMakiko Fujii
Makiko Fujii
PDPeter Ten Dijke
Peter Ten Dijke
VHVaishali Handa
Vaishali Handa
AVAlexander D. Verin
Alexander D. Verin